BIONEXUS GENE LAB CORP (BGLC)
US0906282076 - Common Stock
Taking everything into account, BGLC scores 3 out of 10 in our fundamental rating. BGLC was compared to 48 industry peers in the Trading Companies & Distributors industry. While BGLC has a great health rating, there are worries on its profitability. BGLC is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BGLC had negative earnings in the past year.
In the past year BGLC has reported a negative cash flow from operations.
In multiple years BGLC reported negative net income over the last 5 years.
In multiple years BGLC reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of BGLC (-8.57%) is worse than 95.74% of its industry peers.
BGLC's Return On Equity of -10.04% is on the low side compared to the rest of the industry. BGLC is outperformed by 87.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.57% | ||
| ROE | -10.04% | ||
| ROIC | N/A |
ROA(3y)-6.45%
ROA(5y)-5.78%
ROE(3y)-7.39%
ROE(5y)-5.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BGLC has a Gross Margin of 13.47%. This is amonst the worse of the industry: BGLC underperforms 95.74% of its industry peers.
BGLC's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BGLC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.47% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-0.97%
2. Health
2.1 Basic Checks
BGLC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BGLC has more shares outstanding
BGLC has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BGLC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
BGLC has an Altman-Z score of 3.19. This indicates that BGLC is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BGLC (3.19) is comparable to the rest of the industry.
There is no outstanding debt for BGLC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.19 |
ROIC/WACCN/A
WACC11.75%
2.3 Liquidity
A Current Ratio of 4.98 indicates that BGLC has no problem at all paying its short term obligations.
BGLC has a Current ratio of 4.98. This is amongst the best in the industry. BGLC outperforms 100.00% of its industry peers.
A Quick Ratio of 3.99 indicates that BGLC has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.99, BGLC belongs to the best of the industry, outperforming 97.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.98 | ||
| Quick Ratio | 3.99 |
3. Growth
3.1 Past
BGLC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.85%, which is quite impressive.
The Revenue for BGLC has decreased by -10.48% in the past year. This is quite bad
The Revenue has been growing by 115.55% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)77.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.92%
Revenue 1Y (TTM)-10.48%
Revenue growth 3Y-4.98%
Revenue growth 5Y115.55%
Sales Q2Q%3%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BGLC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for BGLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIONEXUS GENE LAB CORP
NASDAQ:BGLC (1/6/2025, 8:21:11 PM)
Premarket: 0.3321 -0.03 (-8.01%)0.361
-0.1 (-21.64%)
Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryTrading Companies & Distributors
Earnings (Last)
Earnings (Next)
Inst Owners0.37%
Inst Owner Change0%
Ins Owners32.59%
Ins Owner Change0%
Market Cap6.49M
AnalystsN/A
Price TargetN/A
Short Float %1.95%
Short Ratio0.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.7 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.69 | ||
| P/tB | 0.69 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0.52
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.57% | ||
| ROE | -10.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 13.47% | ||
| FCFM | N/A |
ROA(3y)-6.45%
ROA(5y)-5.78%
ROE(3y)-7.39%
ROE(5y)-5.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.41%
GM growth 5Y-0.97%
F-Score2
Asset Turnover0.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 236.42% | ||
| Cap/Sales | 2.42% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.98 | ||
| Quick Ratio | 3.99 | ||
| Altman-Z | 3.19 |
F-Score2
WACC11.75%
ROIC/WACCN/A
Cap/Depr(3y)78.34%
Cap/Depr(5y)145.34%
Cap/Sales(3y)0.66%
Cap/Sales(5y)2.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.92%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.48%
Revenue growth 3Y-4.98%
Revenue growth 5Y115.55%
Sales Q2Q%3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y67.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-619.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-541.16%
OCF growth 3YN/A
OCF growth 5YN/A